Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti

Journal of the International AIDS Society

Volumn 15, Issue 2, 2012, Pages

  Charles, Macarthur ^a,b   Leger, Paul D ^b   Severe, Patrice ^b   Guiteau, Colette ^b   Apollon, Alexandra ^b   Gulick, Roy M ^a   Johnson Jr , Warren D ^a   Pape, Jean W ^a,b   Fitzgerald, Daniel W ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Centers Institute of Infectious Diseases and Reproductive Health   (Haïti)

Author keywords

Adherence; Antiretroviral therapy; Mortality; Second line therapy; Virologic failure

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY WEIGHT; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; COMPARATIVE STUDY; DIARRHEA; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MORTALITY; NEPHROLITHIASIS; NEPHROTOXICITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SURVIVAL RATE; VIROLOGY; VIRUS MUTATION; HAITI; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METHODOLOGY; SURVIVAL; TREATMENT FAILURE;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HAITI; HIV INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 84867466169     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.15.2.17375     Document Type: Article

References (28)

1. UNAIDS [Internet]. 2011 World AIDS Day report [cited December 2011]. Available from: http://www.unaids.org.
2. Hosseinipour MC, van Oosterhout JJ,Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009;23:1127-34.
3. Leger P, Charles M, Severe P, Riviere C, Pape J, Fitzgerald D. 5-year survival of patients with AIDS receiving antiretroviral therapy in Haiti. N Engl J Med. 2009;361:8289.
4. Kantor R, Diero L, Delong A, Kamle L, Muyonga S, Mambo F, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis. 2009;49:454-62.
5. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008;22:1971-7.
6. Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, Boaz I, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS. 2009;23:697-700.
7. van Oosterhout JJ, Brown L, Weigel R, Kumwenda JJ, Mzinganjira D, Saukila N, et al. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health. 2009;14:856-61.
8. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet. 2008;371:1443-51.
9. Moore DM, Awor A, Downing R, Kaplan J, Montaner JS, Hancock J, et al. CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;49:477-84.
10. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 2010;375:123-31.
11. Peck R, Fitzgerald DW, Liautaud B, Deschamps MM, Verdier RI, Beaulieu ME, et al. The feasibility, demand, and effect of integrating primary care services with HIV voluntary counseling and testing: evaluation of a 15-year experience in Haiti, 1985-2000. J Acquir Immune Defic Syndr. 2003;33:470-5.
12. Scaling up antiretroviral therapy in resource-limited settings. Geneva: World Health Organization; 2004.
13. Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med. 2005;353:2325-34.
14. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: WHO; 2010 revision.
15. Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004;57:1107-10.
16. Kitahata MM, Reed SD, Dillingham PW, Van Rompaey SE, Young AA, Harrington RD, et al. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS. 2004;15:803-10.
17. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009;17:138-45.
18. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-24.
19. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005;19:2141-8.
20. Keiser O, Tweya H, Boulle A, Braitstein P, Schecter M, Brinkhof MW, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS. 2009;23:1867-74.
21. Gsponer T, Petersen M, Egger M, Phiri S, Maathuis MH, Boulle A, et al. The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring. AIDS. 2011;26:57-65.
22. Laurent C, Kouanfack C, Laborde-Balen G, Aghokeng AF, Mbougua JB, Boyer S, et al.; Stratall ANRS 12110/ESTHER Study Group. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis. 2011;11:825-33.
23. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Traisaithit P, Barbier S, Techapornroong M, et al.; PHPT-3 Study Group [Internet]. PHPT-3: a randomized clinical trial comparing CD4 vs viral load ART monitoring/switching strategies in Thailand. 18th Conference on Retroviruses and Opportunistic Infections, Paper # 44 [cited May 2012]. Available from: http://www.retroconference.org/2011/ Abstracts/41399.htm.
24. Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2009;53:500-6.
25. Pujades-Rodriguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA. 2010;304:303-12.
26. Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, Mhango B, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med. 2010;11:510-8.
27. Barth RE, Wensing AM, Tempelman HA, Moraba R, Schuurman R, Hoepelman AI. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa. AIDS. 2008;22:2210-2.
28. Charles M, Noel F, Leger P, Severe P, Riviere C, Beauharnais CA, et al. Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals. Bull World Health Organ. 2008;86:970-7.